Table 1.

Molecular alterations acquired upon resistance to targeted therapy combinations in BRAF-mutant CRC cell lines

DrugsCell lineEGFRKRASNRASMAP2K1MAP2K2BRAF Gene CNV
D + TVACO432WTWTWTL115PWTNone
V + SWiDrEGFR ampl.WTWTWTWTNone
E + CHROC87WTG13DWTWTWTNone
VACO432WTA146TWTWTWTNone
D + CVACO432WTA146TWTWTWTNone
WiDrWTKRAS ampl.WTWTWTNone
V + CVACO432 R.AWTG12DWTWTWTNone
VACO432 R.BG465RWTWTWTWTNone
E + C + AVACO432WTA146V A146TWTWTWTNone
S + CHROC87WTWTWTV211DWTNone
WiDrWTWTWTWTWT600E ampl.